Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab or Mosunetuzumab + GemOx in R/R DLBCL/HGBCL
NCT04313608Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of glofitamab and mosunetuzumab in diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma (HGBCL) (2 arms), sponsored by Roche. Primary endpoints: Number of Deaths Due to Adverse Events, Number of Treatment Discontinuations Due to Adverse Events and 2 more. Started Jun 2020; status: completed.
02
Drugs
glofitamabmosunetuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT04313608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313608.